leadXPro – structure-based drug design on membrane protein targets at SwissFEL

Content Provider	Semantic Scholar
Author	Cheng, Robert K. Y. Markovic, Sara Botte, Mathieu Hennig, Markus
Copyright Year	2016
Abstract	Serial femtosecond crystallography (SFX) using X-ray free electron laser (XFEL) significantly increases the realm of possibility of obtaining structural information from membrane proteins. So far access to the technology is limited to 2 XFEL facilities (LCLS, USA and SACLA, Japan) severely restricting application of this revolutionary technique. LeadXpro brings the industrial expertise of structure-based drug design on membrane protein and has premium access to SwissFEL when it starts operation towards the end of 2017. With capabilities for gene-to-structure, we employ a diversity of technique and industrial expertise including the crystallization of membrane protein (GPCRs, transporters and ion channels), traditional/serial crystallography and electron microscopy, coupled to easy access to synchrotron beamlines at the SLS and the collective scientific expertise at the Paul Scherrer institute. In collaboration with scientists at the SLS, we are also committed to further develop technology for application in serial crystallography. Our goal is to apply these methods for structure-based drug discovery to study difficult membrane protein target implicated in a variety of human diseases. Here we describe the drug discovery pipeline and technology we employed at LeadXPro, and show some examples of the range of activities in the company.
File Format	PDF HTM / HTML
DOI	10.1107/S2053273316096820
Volume Number	72
Alternate Webpage(s)	http://journals.iucr.org/a/issues/2016/a1/00/a54318/a54318.pdf
Alternate Webpage(s)	https://doi.org/10.1107/S2053273316096820
Language	English
Access Restriction	Open
Content Type	Text
Resource Type	Article